Monarch Therapeutics is developing adaptable cellular immunotherapies for solid tumors. Its modular platform uses small-molecule-based adaptors to redirect engineered immune cells toward different tumor targets. The University of Pittsburgh spinout is pursuing more flexible cancer treatments, with longer-term goals that include orally available adaptors and lower manufacturing costs. [1]
Launched in December 2023, Monarch brings together scientific cofounders Jason Lohmueller and Alexander Deiters with Christopher Potts, Nicholas Ostrout and Matthew Hewitt. In May 2025, SNAP Biosciences licensed Monarch’s adaptor technology for its SNAP-CAR NK platform. [1] [2] [3]